PHONE: 517.536.8210
FAX: 517.536.8205


TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions


Winter 2018 Newsletter

A Note from the President The Super Bowl may be over, but our team is always training to compete against Super Bugs! Super bugs, or multi-drug resistant bacteria, are bacteria that cannot be killed using two or more antibiotics. Any species of bacteria can become a super bug, and misusing antibiotics is the leading factor contributing to this growing problem. Our winning streaks – bacteria on agar plates. A 2015 White House Report identified several super bug threats, many of which we use in our research here at TransPharm. We have validated studies using carbapenem-resistant enterobacteriaceae (CRE), methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), Acinetobacter, and many other super bugs. Have a question about which pathogens and models we specialize in? Contact us at your convenience. There are no half-time shows here; we work around the clock to complete studies for our fans. We don’t have turf or a stadium, but we pride ourselves on being champions in our field for the past 10 years. Several of our clients have published data on novel therapeutics to combat super bugs, and we think that’s something worth cheering for. Daniel Ross President & CEO In the Lab Recently, we have had several requests for our murine model of cecal ligation and puncture (CLP). CLP is the gold standard for inducing and studying sepsis, a serious condition characterized by systemic inflammation in response to widespread infection. More than 1.5 million Americans get sepsis each year, with about 250,000 of those patients dying annually ( To perform CLP, the cecum and adjoining instestine are exposed and the cecum is tightly ligated at its base below the ileo-cecal valve (top photo). Then, the cecum is punctured with a needle (bottom photo) and gently squeezed to extrude a small amount of feces from the puncture sites. The cecum is returned to the peritoneal cavity. Between 6 and 12 hours post-procedure, mice develop clinical signs of sepsis including lethargy, and diarrhea. Death occurs between 24 and 60 hours post-CLP, and mortality rates are predictable based on the size of the needle used for cecal perforation. Contact us for a no-obligation quote and professional consultation. Santiago R. Lopez, Ph.D. Chief Scientific Officer Come see us at ASM Microbe 2018! Members of the TransPharm team will be attending the American Society for Microbiology (ASM) Microbe...

Read More

Fall 2017 Newsletter

A Note from the President The year is coming to a close and 2018 is right around the corner. It’s hard to believe, but January will mark TransPharm’s 10-year anniversary. Our company started with just three employees, but ten years later we have quadrupled in size. The total revenue our first year was $147k; now we do over $2 million annually. Time flies when you’re having fun! To celebrate our landmark anniversary and as a thank you to our clients, we are offering 10% off all studies booked by December 21st. See below for more details. Also, we’d like to remind you that TransPharm will be closed starting Monday, December 25th and will reopen on Tuesday, January 2nd. The last day for animal deliveries is December 18th, with studies ending on the 22nd. Studies for early January (and any that you wish to be 10% off!) should be booked by December 21st. We will be checking email periodically, and this is the best way to reach us during our break. We wish you and yours a joyous holiday season and a happy new year. Daniel Ross President & CEO 10% Off ALL Studies! Celebrate our 10-year anniversary with 10% off! All studies booked* by 12/21/2017 are eligible for the discount. Contact Marci for a quote today! *Signed quotes and a purchase order must be received by end of business on Thursday, December 21, 2017. In the Lab TransPharm has added a new animal model of induced chronic osteomyelitis (bone infection). Osteomyelitis results in pain, loss of mobility, and significant morbidity. Current treatment requires prolonged antibiotic therapy and surgical debridement of sequestra (dead bone). Due to poor drug penetration into the bone and an increase in antibiotic-resistant bacteria, there is an urgent need for novel therapeutics. Our model serves as a screening tool to identify which antimicrobials are most clinically efficacious. Animals are challenged via injection into the cancellous bone marrow through the anterior surface of the proximal tibia (see photo). The infection is allowed to incubate for up to 4 weeks before the tibia is harvested for CFU enumeration. The induced chronic osteomyelitis model is currently available for S. aureus and S. epidermidis infections in Sprague-Dawley rats. Additional validations are available...

Read More

Summer 2017 Newsletter

A Note from the President It’s been a busy summer here at TransPharm and we are on track for another record year. Our team has been hard at work and we’re excited to share an inside look at what we do. The video below gives a great overview of our role in preclinical infectious disease research. It highlights our niche focus – animal models of bacteria, viruses, parasites, and fungi – which has cultivated an expertise that sets us apart from other contract research organizations. As specialists, we can serve as professional consultants to help you design a study that meets both your needs and your budget. You’ll also get a glimpse of our state-of-the-art laboratory and animal care facilities, as well as hear about how we manage such quick turn-around times for our clients. We have a passion for knowledge and scientific discovery and feel honored to play even a small part in the drug development process. It is our goal that our work will contribute to new and potentially life-saving therapies. We hope you enjoy the video and don’t forget to subscribe to our YouTube channel to see future content. Daniel Ross President & CEO In the Lab We are searching for TransPharm’s Next Top Model! Our team has been focused on validating new murine models of infectious disease, including Haemophilus influenzae pneumonia, Staphylococcus epidermidis peritonitis, Streptococcus pyogenes soft tissue infection, and Acinetobacter baumannii deep wound infection. Upcoming validations will follow-up on the 2017 summer internship program projects as well as validating new comparators against H. influenzae, P. acnes, and VRE. Contact us today to request a validation or no-obligation quote. Speaking of our internship program, it was featured in a recent edition of the Brooklyn Exponent. All four of our 2017 interns – Paige, Brandon, Jen, and Trevor – did a fantastic job in the lab. We are looking forward to meeting next year’s applicants! Santiago R. Lopez, Ph.D. Chief Scientific Officer Publications Many of our clients have published their research and acknowledged TransPharm’s role in their work. Check out a few of the manuscripts and poster presentations based on studies we’ve completed, including a P. acnes skin infection, a pulmonary model of Pseudomonas aeruginosa, a C. difficile gastrointestinal infection, as well as models of candidiasis, aspergillosis, and cecal ligation and puncture...

Read More

Spring 2017 Newsletter

A Note from the President Spring has finally sprung in Michigan and things are looking especially sunny here at TransPharm. We celebrated our best first quarter in history, and the first intern of our summer internship program is finishing up validation of an A. baumanii pulmonary infection model. Lunches are spent at the picnic table on our patio, and everyone is enjoying a newly constructed trail which weaves through the woods to a pond on the property. Warmer weather isn’t the only change we’ve noticed. Today’s economy relies on technology more than ever before, and a growing number of customers want to interact with businesses in a way that is most convenient for them. For this reason, our team has decided to pursue a different marketing strategy than in years past. In lieu of attending the American Society for Microbiology conference in June, we will be using our resources to expand our digital presence. Keep your eyes open for original media content highlighting our niche services, and be sure follow us on Facebook for the latest and greatest. Daniel Ross President & CEO The trail on our property leads through the woods to a pond nestled among the willow trees. Wild geraniums (above) and lily of the valley grow along the trail. In the Lab Many bacteria live in our gut and on our skin, usually without causing problems. However, serious infections can occur when these bacteria become resistant to antibiotics. Vancomycin-resistant enterococci, or VRE, are one such threat. Although healthy people are unlikely to become infected with VRE, those who are hospitalized or have weakened immune systems are especially at risk. TransPharm has a well-established murine model of VRE colonization in the gastrointestinal tract, one of the most common sites for infection. Antibiotic pre-treatment provides consistent results, with fecal shedding peaking on Days 3-5 and observed through Day 15. Our screening studies are flexible enough to accommodate studies with prophylactic and/or daily dosing. We also have personnel and areas of our facility dedicated specifically to VRE work. Contact us today for a quote! Santiago R. Lopez, Ph.D. Chief Scientific Officer Marci Peek promoted to Senior Protocol Specialist We are excited to announce that Marci Peek has been promoted to Senior...

Read More

Winter 2017

A Note from the President January 2017 marked our 9 year anniversary and the close of another great year here at TransPharm. With 17 new clients in 2016, the TransPharm family now spans over 6 continents. As a result of our continued growth, we were able to reach a major milestone in November: a total of $10M in revenue since I founded the company in 2008. Increased demand also allowed us to welcome some new faces to our team – Brianne Fiero (Associate Scientist) in April, and Brittany Dixon (Scientific Writer) and Emily Gilles (Laboratory Technician) in October. 2016 was also a year of physical growth. A 2,100 sq. ft. addition to our facility, including an expanded animal vivarium and a procedure room, was completed in May. This new space contains both a negative pressure room and a positive pressure room, with corresponding bioBUBBLE® enclosures in each, meaning separate, dedicated areas for C. difficile and germ-free work, respectively. The renovations have already proven advantageous to our clients who currently work in the C. difficile therapy development field. Please contact us for more information. Finally, I’d like to extend an open invitation to visit us here at TransPharm. We wouldn’t be celebrating these successes without our clients, and we’d love the opportunity to meet you personally and provide a tour of our facilities. Thank you for your business and we look forward to working with you in the new year. Daniel Ross President & CEO               In the Lab This past summer, six local high school and college students interested in a career in life science participated in TransPharm’s internship program. Each student spent two weeks working on their own model validation project focused on one of the ESKAPE pathogens. These bacteria, listed below, cause the majority of US hospital infections and are increasingly resistant to current antimicrobials.   Enterococcus faecium Staphylococcus aureus Klebsiella pnuemonia Acinetobacter baumannii Pseudomonas aeruginosa Enterobacter species   Thanks to the hard work of these motivated students and historical data, TransPharm now has a validated model for all ESKAPE pathogens, with some pathogens having several models available. Contact us today for quotes or more information. Due to the popularity and...

Read More

Fall 2014

A Note from the President Another year has gone by quickly and 2015 is right around the corner. This January marks our seven-year anniversary. It is hard to believe that eight years has passed since Pfizer R & D closed its doors in Ann Arbor, Michigan. January 22nd, 2007 was the announcement day that made all of us wonder what would happen after Pfizer. I was one of the lucky ones that had a plan shortly after the announcement and that plan was founding TransPharm Preclinical Solutions. We incorporated on April 13th, 2007, started renovation to the lab in September of that year, and opened our doors on January 2nd, 2008. Today we are considered a global leader for Infectious Disease research and have generated more than 6 million in revenue with over 60 clients around the world. TransPharm has never been stronger and we are eager to see what the future holds for us. During the holidays, we are very thankful to do what we love and even more thankful to you for allowing us to do this important work. Daniel Ross President and CEO Slight Increase in Pricing Starting in January, TransPharm will be increasing the cost of our studies due to increases in costs from some of our suppliers. We expect the increase to be 5% across the board for all studies, but this could vary depending on study design. Studies booked for January that are scheduled in December will remain at the current price structure. Holiday Schedule TransPharm will be closed from around noon on December 24th until January 5th. All studies must end no later than the 24th with preliminary data following mid-day. All mouse orders scheduled for January 5th must be placed before December 24th. No animals will be housed on-site during this closure. Now is the time to get your studies scheduled for the new year....

Read More